List view / Grid view
28 January 2015 | By Genticel
Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces its cash ans cash equivalents and liquid investments position and its highlights from the fourth quarter of 2014...
27 January 2015 | By TxCell
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces the receipt of EUR 1.7 million from Bpifrance...
27 January 2015 | By Andrew Lloyd & Associates
The Data and Safety Monitoring Board (DSMB) identified no safety concerns that would require making changes to the conduct of the study...
22 January 2015 | By UCL
Syncona LLP and UCL Business PLC, the wholly-owned technology transfer company of University College London, announce the creation of Autolus Limited...
22 January 2015 | By B3C newswire
New Oncology and the University Hospital Oslo announced today that they have entered into a collaboration to identify alterations in cancer-related tumour genes that predict a patient’s response or resistance to targeted therapies...
16 January 2015 | By Treeway B.V.
Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS, have announced a collaboration with uniQure N.V., a leading gene therapy company, (NASDAQ:QURE), to develop a gene therapy treatment for ALS...
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
13 January 2015 | By B3C newswire
First-in-human study in advanced-stage Glaucoma to begin in 1H2015...
13 January 2015 | By Biodesix, Inc.
Biodesix, Inc., announced that the company increased the size of its offering of series E preferred shares in a follow-on sale...
13 January 2015 | By Roche
Roche, Meiji Seika Pharma (Meiji) and Fedora announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development...
13 January 2015 | By Astrazeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses...
12 January 2015 | By Oryzon
Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015...
12 January 2015 | By Roche
Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer...
12 January 2015 | By Kymab
Combination of Kymab’s unique antibody platform and cytokine technologies expected to deliver enhanced efficacy and tolerability...
9 January 2015 | By Roche
FDA Approves Roche’s Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets. cobas TaqScreen MPX Test, v2.0 offers enhanced sensitivity and workflow advantages...
